Thoracic surgery clinicsHumansNeoadjuvant TherapyProtein Kinase InhibitorsLung NeoplasmsCarcinoma
Neoadjuvant Tyrosine Kinase Inhibitors.
Gavitt A Woodard, Ryan J Kramer, Collin M Blakely
Published: 202610.1016/j.thorsurg.2025.08.004
Abstract
Neoadjuvant tyrosine kinase inhibitor (TKI) therapy has appeal given the potential for early systemic disease control and tumor downstaging prior to surgery. Until recently, data has have come from smaller series with outcomes from larger trials, inc…
Preview only. Read the full abstract at the source